Nanogroup SA (NNG) - Total Liabilities

Latest as of June 2025: zł5.26 Million PLN ≈ $1.45 Million USD

Based on the latest financial reports, Nanogroup SA (NNG) has total liabilities worth zł5.26 Million PLN (≈ $1.45 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Nanogroup SA to track the company's year-over-year net asset growth rate.

Nanogroup SA - Total Liabilities Trend (2014–2024)

This chart illustrates how Nanogroup SA's total liabilities have evolved over time, based on quarterly financial data. See NNG free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Nanogroup SA Competitors by Total Liabilities

The table below lists competitors of Nanogroup SA ranked by their total liabilities.

Company Country Total Liabilities
Alpha Group International plc
LSE:ALPH
UK GBX294.65 Million
Alcom Group Bhd
KLSE:2674
Malaysia RM625.34 Million
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
NASDAQ:ZJYL
USA $23.80 Million
Seojin Automotive Co.Ltd
KQ:122690
Korea ₩1.62 Trillion
Jullundur Motor Agency (Delhi) Limited
NSE:JMA
India Rs749.82 Million
INTERSHOP Communications Aktiengesellschaft
XETRA:ISHA
Germany €22.65 Million
Crypto Blockchain Industries SA
PA:ALCBI
France €14.13 Million
Iz Hayvancilik Tarim ve Gida Sanayi Ticaret AS
IS:IZINV
Turkey TL39.95 Million

Liability Composition Analysis (2014–2024)

This chart breaks down Nanogroup SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NNG stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.40 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.49 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.32 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Nanogroup SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Nanogroup SA (2014–2024)

The table below shows the annual total liabilities of Nanogroup SA from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 zł4.01 Million
≈ $1.10 Million
+15.45%
2023-12-31 zł3.47 Million
≈ $955.64K
-69.58%
2022-12-31 zł11.42 Million
≈ $3.14 Million
-4.36%
2021-12-31 zł11.94 Million
≈ $3.29 Million
+5.91%
2020-12-31 zł11.27 Million
≈ $3.10 Million
-13.75%
2019-12-31 zł13.07 Million
≈ $3.60 Million
+13.52%
2018-12-31 zł11.51 Million
≈ $3.17 Million
+36.42%
2017-12-31 zł8.44 Million
≈ $2.32 Million
+25.86%
2016-12-31 zł6.70 Million
≈ $1.85 Million
+1227.13%
2015-12-31 zł505.16K
≈ $139.03K
-64.92%
2014-12-31 zł1.44 Million
≈ $396.29K
--

About Nanogroup SA

WAR:NNG Poland Biotechnology
Market Cap
$21.91 Million
zł79.61 Million PLN
Market Cap Rank
#24760 Global
#242 in Poland
Share Price
zł2.48
Change (1 day)
+0.20%
52-Week Range
zł2.29 - zł3.12
All Time High
zł13.00
About

NanoGroup S.A. operates as a biotechnology company in Poland. The company develops and licenses early-stage pre-clinical and IND solutions to international biotech and pharma companies. It also manages a portfolio of companies that manages projects for the need of modern medicine in the field of oncology and transplantology. The company was incorporated in 2016 and is based in Warsaw, Poland.